1Q26 consolidated OP turns to KRW 6.7B profit, net profit KRW 132.2B (incl. KRW 119.5B valuation gain)
Operating results: 1Q26 consolidated revenue KRW 6.58B (vs. KRW 7.22B in prior year, -8.9%), operating profit KRW 667M (vs. KRW 349M, +91%) turning to black. Net profit surged to KRW 13.22B (vs. KRW 194M) mainly due to one-off valuation gain of KRW 11.95B from investment in Mediana etc.
Financial health: Debt ratio 9.2%, borrowings only KRW 750M. Ample liquidity with cash & equivalents KRW 4.0B and short-term financial assets KRW 28.9B. Trade receivables loss allowance decreased to KRW 1.30B (from KRW 2.37B at year-end), reducing credit risk.
Business segments: Medical diagnostic devices revenue KRW 3.90B (vs. KRW 4.76B in prior quarter), assistive technology devices revenue KRW 2.69B (vs. KRW 2.46B). R&D expenses KRW 1.14B (17.3% of revenue).
Subsidiaries: HIMS (US) and China subsidiary reported net losses of KRW 155M and KRW 44M respectively. Joint venture SelvasInvision recorded equity method loss of KRW 9M.
Dividends and shareholder returns: No dividends paid, no treasury share buyback or cancellation. Stock options outstanding: 340,000 shares at exercise price of KRW 3,332.